Bone induction filling scaffold material as well as preparation method and application thereof

The bone induction filling scaffold material, composed of amniotic membrane particles cross-linked with polyethylene glycol derivatives and hydroxyapatite, addresses stability and induction issues, providing stable, antibacterial, and regenerative bone repair without additional fixation.

CN119055833APending Publication Date: 2024-12-03MOBILE MEDICAL TECH (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249940.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing bone filling materials suffer from poor mechanical stability, require additional fixation after implantation, and have insufficient bone induction ability, making them cumbersome to use and less effective in treating bone defects.

Method used

A bone induction filling scaffold material is formed by loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles, cross-linking them with polyethylene glycol derivatives, and mixing with hydroxyapatite to create a three-dimensional scaffold structure, ensuring uniform distribution and mechanical stability without the need for additional fixation, while promoting cell proliferation and differentiation.

Benefits of technology

The scaffold material achieves good mechanical stability, uniform distribution, and effective bone induction, reducing inflammation and promoting bone repair and regeneration, with antibacterial properties and long-lasting mechanical strength.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055833A_ABST
    Figure CN119055833A_ABST
Patent Text Reader

Abstract

The invention provides an osteoinductive filling scaffold material. The osteoinductive filling scaffold material comprises an amnion material formed by loading polyhexamethylene biguanide hydrochloride on amnion particles, hydroxyapatite and a polyethylene glycol derivative crosslinked with the amnion material, wherein the mass ratio of the hydroxyapatite to the amnion material to the polyethylene glycol derivative is (3-30): 1: (1-10). According to the invention, an amnion material formed by loading polyhexamethylene biguanide hydrochloride on amnion particles, the amnion material and a polyethylene glycol derivative are subjected to mutual crosslinking, and hydroxyapatite is mixed to form the bone induction filling scaffold material, so that a three-dimensional scaffold structure is formed, and uniform distribution of the amnion material in the bone induction filling scaffold material is realized. When the bone induction filling scaffold material is adhered to a bone defect, the three-dimensional scaffold structure enables the bone induction filling scaffold material to have good mechanical stability, so that additional fixation is not needed, and the amniotic membrane material contained in the components can promote proliferation and differentiation of recruitment cells to realize repair and regeneration of the bone defect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical materials, and in particular to a bone induction filling scaffold material, a preparation method and application thereof. Background Art

[0002] For the treatment of bone defects, autologous bone is the gold standard for bone defect transplantation materials. It has a low risk of immune rejection, good biocompatibility, and strong bone growth induction and osteogenesis properties. It is widely used to treat post-traumatic diseases such as fractures, delayed union, nonunion, and malformation. However, since autologous bone needs to be collected from the patient's own body, there are certain risks, and the source is relatively limited and unstable. Donor autologous bone may not be able to meet the needs of repairing larger bone defects. Even for the most ideal recipients, autologous bone transplantation surgery will still produce many complications, which to a certain extent limits its application.

[0003] As one of the major challenges in the field of tissue engineering, the treatment of bone defects has always been a hot topic in the field of tissue engineering. Collagen and hydroxyapatite are the most abundant proteins and main components in natural bones, respectively. Due to their excellent biocompatibility and biodegradability, they are currently used as biomimetic composite materials in tissue engineering.

[0004] However, the existing bone filling materials or powdered bone filling materials have poor mechanical stability, need to be fixed after implantation, and the implantation method is relatively cumbersome. In addition, there is a problem of insufficient bone induction ability. Therefore, it is necessary to provide a bone induction filling scaffold material to solve the problems existing in the prior art. Summary of the invention

[0005] The present invention aims to solve the technical problems that existing bone filling materials or powdered bone filling materials have poor mechanical stability, need to be fixed after implantation, and are relatively complicated to implant, and have insufficient bone induction ability.

[0006] To achieve the above objectives, in a first aspect, the present invention provides an osteoinductive filling scaffold material, comprising:

[0007] Amniotic membrane material formed by amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride, hydroxyapatite and polyethylene glycol derivative cross-linked with the amniotic membrane material; wherein the mass ratio of the hydroxyapatite, the amniotic membrane material and the polyethylene glycol derivative is 3-30:1:1-10.

[0008] The present invention forms an amniotic material by loading polyhexamethylene biguanide hydrochloride with amniotic membrane particles, and the amniotic membrane material is cross-linked with polyethylene glycol derivatives, and then mixed with hydroxyapatite to form an osteoinductive filling scaffold material, so as to form a three-dimensional scaffold structure, and realize uniform distribution of the amniotic membrane material in the osteoinductive filling scaffold material. When the osteoinductive filling scaffold material adheres to the bone defect, the three-dimensional scaffold structure, on the one hand, enables the osteoinductive filling scaffold material to have good mechanical stability, and on the other hand, the polyethylene glycol derivatives can react with the amino groups on the human tissue, so that the osteoinductive filling scaffold material is bonded to the human body, so that no additional fixation is required, and the amniotic membrane material contained in the composition can promote the proliferation and differentiation of recruited cells, so as to realize the repair and regeneration of bone defects.

[0009] In a preferred example, the polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.

[0010] In a preferred example, the multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.

[0011] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 3000-20000 Daltons.

[0012] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 8000-15000 Daltons.

[0013] In a preferred example, in the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.

[0014] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1-10:1.

[0015] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 3-7:1.

[0016] In a preferred example, the degree of polymerization of the polyhexamethylene biguanide hydrochloride is 7-17.

[0017] In a second aspect, the present invention further provides a method for preparing an osteoinductive filling scaffold material, comprising the following steps:

[0018] S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material;

[0019] S2: Mixing the amniotic membrane material, hydroxyapatite and polyethylene glycol derivative solution to obtain the bone-inducing filling scaffold material.

[0020] In a preferred example, the S1 is specifically:

[0021] Putting the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles into a hydrophilic organic solvent, wherein the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent is 1:10-100, to obtain a mixed solution;

[0022] Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred solution;

[0023] Filtering the stirred solution to obtain a filtered solution;

[0024] The filtered solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.

[0025] In a preferred example, the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent in S1 is 1:50.

[0026] In a preferred example, the particle size of the amniotic membrane particles is 1 μm to 100 μm.

[0027] In a preferred example, the particle size of the amniotic membrane particles is 40 μm to 70 μm.

[0028] In a preferred example, the mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.

[0029] In a preferred example, the solvent of the polyethylene glycol derivative solution is a buffer solution that is isotonic with human blood.

[0030] In a preferred example, the hydrophilic organic solvent includes at least one of ethanol, acetone and dimethylformamide.

[0031] In a preferred example, the concentration of the hydrophilic organic solvent is 75 wt % to 95 wt %.

[0032] In a preferred example, the concentration of the hydrophilic organic solvent is 80 wt % to 90 wt %.

[0033] In a preferred example, S0 is also included before S1;

[0034] S0: The amniotic membrane is sequentially washed, homogenized, freeze-dried and crushed to obtain the amniotic membrane particles.

[0035] In a third aspect, the present invention further provides an application of an osteoinductive filling scaffold material, wherein the application is an application of the above-mentioned osteoinductive filling scaffold material in the preparation of a drug for treating bone defects.

[0036] The beneficial effects of the present invention are:

[0037] (1) The amniotic membrane material is formed by loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles, and then the amniotic membrane material is cross-linked with polyethylene glycol derivatives and mixed with hydroxyapatite to form an osteoinductive filling scaffold material to form a three-dimensional scaffold structure and achieve uniform distribution of the amniotic membrane material in the osteoinductive filling scaffold material. When the osteoinductive filling scaffold material adheres to the bone defect, the three-dimensional scaffold structure gives it good mechanical stability, so no additional fixation is required, and the amniotic membrane material contained in the composition can promote the proliferation and differentiation of recruited cells to achieve the repair and regeneration of bone defects.

[0038] (2) The bone-inducing filling scaffold material of the present invention can fully exert the biological activity of the amniotic membrane, reduce inflammation, and at the same time exert the inductive effect of the three-dimensional scaffold to promote bone repair and regeneration.

[0039] (3) The bone-inducing filling scaffold material of the present invention has good antibacterial properties because it contains polyhexamethylene biguanide hydrochloride. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 It is a process flow chart of the method for preparing the bone induction filling scaffold material according to an embodiment of the present invention;

[0041] Figure 2 It is a schematic diagram of the structure of the cleaning fixture used in the embodiment of the present invention. DETAILED DESCRIPTION

[0042] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme in the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work belong to the scope of protection of the present invention. Unless otherwise defined, the technical terms or scientific terms used herein should be the usual meanings understood by people with general skills in the field to which the present invention belongs. "Including" and similar words used in this article mean that the elements or objects appearing before the word include the elements or objects listed after the word and their equivalents, without excluding other elements or objects. Unless otherwise specified, the "connection" described in this article can be a direct connection or an indirect connection, that is, connected through an intermediate.

[0043] In view of the problems existing in the existing technology, such as Figure 1 As shown, in this example, the present invention provides a method for preparing an osteoinductive filling scaffold material, comprising the following steps:

[0044] S0: washing, homogenizing, freeze-drying and crushing the amniotic membrane in sequence to obtain the amniotic membrane particles;

[0045] S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material;

[0046] S2: Mixing and cross-linking the amniotic membrane material, hydroxyapatite and polyethylene glycol derivative solution to obtain the bone-inducing filling scaffold material.

[0047] In a further example, S0 is specifically:

[0048] Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp, place it in a saline solution 3-5 times the mass of the amniotic membrane for 30-60 minutes, repeat the cleaning 11-15 times to obtain the cleaned amniotic membrane. This is to clean and remove 99%-99.99% of the soluble lipids and viscous polysaccharides in the amniotic membrane;

[0049] The cleaned amniotic membrane is placed in purified water with a mass 10 to 20 times that of the cleaned amniotic membrane, and homogenized for 2 to 10 minutes using a colloid mill with a gap of 0.05 to 0.3 mm between the moving and static grinding discs to obtain a homogenized amniotic membrane;

[0050] The homogenized amniotic membrane is freeze-dried at a temperature of -80°C to -25°C and a pressure of 0.01 mbar to 0.5 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;

[0051] The freeze-dried amniotic membrane is mechanically pulverized into particles with a particle size of 1 μm to 100 μm to obtain amniotic membrane particles.

[0052] In this example, amniotic membrane particles are obtained through a two-step process of homogenization and crushing. Homogenization is the crushed amniotic membrane obtained by shearing and squeezing between grinding discs when the amniotic membrane is wet, that is, the amniotic membrane after homogenization. The amniotic membrane particles obtained by homogenizing the wet amniotic membrane are in the form of silk flocs and have a larger specific surface area. Freeze-drying the homogenized amniotic membrane is more conducive to maintaining its loose structure. The homogenized amniotic membrane has an extremely high specific surface area, but due to physical adhesion, the freeze-dried amniotic membrane is sponge-like, and the amniotic membrane particles are finally obtained through the process of physical crushing.

[0053] The physical form of the amniotic membrane material will affect the strength of the osteoinductive filling scaffold material. In this example, the prepared amniotic membrane material is dispersed in the solution in a filamentous state, and the amniotic membrane material dispersed in the osteoinductive filling scaffold material can prevent the matrix from dislocation movement, thereby enhancing the effect of the osteoinductive filling scaffold material.

[0054] In a further example, the freeze-dried amniotic membrane is a loose sponge-like solid.

[0055] In a further example, the structural schematic diagram of the cleaning fixture is as follows: Figure 2As shown, the cleaning clamp is a stainless steel mesh frame. The amniotic membrane after blunt peeling is spread flat on the clamp and then clamped and locked. This can prevent the amniotic membrane from curling and swelling during the cleaning process, and at the same time squeeze out the water-soluble components in the amniotic membrane to ensure that the removal rate of viscous polysaccharides such as hyaluronic acid and soluble lipids is more than 99%.

[0056] In a further example, S1 is specifically:

[0057] placing the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles in a hydrophilic organic solvent to obtain a mixed solution;

[0058] Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred solution;

[0059] Filtering the stirred solution to obtain a filtered solution;

[0060] The filtered solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.

[0061] In the process of loading the amniotic membrane particles with polyhexamethylene biguanide hydrochloride, the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles are placed in a hydrophilic organic solvent to obtain a mixed solution, and the polyhexamethylene biguanide hydrochloride is loaded on the amniotic membrane particles due to electrostatic adsorption. Moreover, under the conditions of infiltration with a hydrophilic organic solvent and freeze drying, water absorption and agglomeration of the amniotic membrane material during the drying process can be avoided.

[0062] The specific principle is: under the condition of a certain concentration of hydrophilic organic solvent, such as ethanol solution, the electrostatic interaction between the carboxyl groups of the protein in the amniotic membrane particles and the polyhexamethylene biguanide hydrochloride is weakened, so that the carboxyl groups of the amniotic membrane particles adsorb most of the polyhexamethylene biguanide hydrochloride, while part of the polyhexamethylene biguanide hydrochloride is ionized into the ethanol solution, so that the entire system reaches ionization equilibrium, and finally the polyhexamethylene biguanide hydrochloride is evenly loaded on the amniotic membrane powder.

[0063] In a further example, the particle size of the amniotic membrane particles is 1 μm to 100 μm.

[0064] In a further example, the mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.

[0065] In a further example, the solvent of the polyethylene glycol derivative solution is a buffer solution that is isotonic with human blood.

[0066] In a further example, the hydrophilic organic solvent includes at least one of ethanol, acetone, and dimethylformamide.

[0067] In a further example, the concentration of the hydrophilic organic solvent is 75wt% to 95wt%. Polyhexamethylene biguanide hydrochloride has an extremely high positive charge density. The main component of the amniotic membrane is collagen, which contains negatively charged carboxyl groups. Polyhexamethylene biguanide hydrochloride is electrostatically loaded on the amniotic membrane particles. Since both have strong electrostatic effects, in order to achieve uniform loading, it is necessary to weaken their electrostatic effects. Under the conditions of 75%-95% concentration of hydrophilic organic solvent, the electrostatic effect can be weakened, ionization equilibrium can be achieved, and polyhexamethylene biguanide hydrochloride is evenly loaded on the amniotic membrane.

[0068] In this example, a bone-inducing filling scaffold material is prepared according to the preparation method of the bone-inducing filling scaffold material of the above example, including: amniotic membrane material formed by amniotic membrane particles loading polyhexamethylene biguanide hydrochloride, hydroxyapatite, and polyethylene glycol derivatives cross-linked with the amniotic membrane material; wherein the mass ratio of the hydroxyapatite, the amniotic membrane material and the polyethylene glycol derivative is 3-30:1:1-10. The present invention forms an amniotic membrane material by loading polyhexamethylene biguanide hydrochloride with amniotic membrane particles, and the amniotic membrane material is cross-linked with the polyethylene glycol derivative, and then mixed with hydroxyapatite to form a bone-inducing filling scaffold material to form a three-dimensional scaffold structure, and to achieve uniform distribution of the amniotic membrane material in the bone-inducing filling scaffold material. When the bone-inducing filling scaffold material adheres to the bone defect, the three-dimensional scaffold structure gives it good mechanical stability, so no additional fixation is required, and the amniotic membrane material contained in the component can promote the proliferation and differentiation of recruited cells to achieve the repair and regeneration of bone defects.

[0069] In the prior art, liquid-to-liquid crosslinking is more likely to form a uniform gel. In this example, in order to achieve effective crosslinking between polyethylene glycol and solid-phase amniotic membrane, the solid-phase amniotic membrane needs to be evenly dispersed in the solution and have enough crosslinking sites. Therefore, in this example, the amino groups of the proteins in the amniotic membrane particles can be crosslinked with the succinimide active esters in the polyethylene glycol derivatives. In order to further increase the crosslinking sites, the amniotic membrane particles are loaded with polyhexamethylene biguanide hydrochloride. Polyhexamethylene biguanide hydrochloride has an extremely high positive charge density. The amniotic membrane modified with polyhexamethylene biguanide hydrochloride, in addition to the original amniotic membrane amino crosslinking sites, also greatly increases the polycationic crosslinking sites, thereby enhancing the crosslinking density with the polyethylene glycol derivatives.

[0070] Compared with the traditional polyethylene glycol derivative cross-linking agent polylysine, the amniotic membrane-containing bone-inductive filling scaffold material of this example is a three-dimensional network gel formed by cross-linking amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride and polyethylene glycol derivatives, and is also loaded with hydroxyapatite, so that it has higher strength and good mechanical stability, and a longer degradation cycle. The strength of the bone-inductive filling scaffold material of the present invention can still be maintained at more than 80% after one week. The stability of the bone-inductive filling scaffold material is crucial to the continuous tissue regeneration process.

[0071] In a preferred example, the polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.

[0072] In a preferred example, the multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.

[0073] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 3000-20000 Daltons.

[0074] In a preferred example, in the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.

[0075] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1-10:1.

[0076] In a preferred example, the degree of polymerization of the polyhexamethylene biguanide hydrochloride is 7-17.

[0077] In a preferred example, the osteoinductive filling scaffold material is applied to the bone defect and can bond with the amino group of the tissue protein at the application site. The three-dimensional scaffold material can firmly adhere to the bone defect and promote bone tissue repair.

[0078] Example 1

[0079] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;

[0080] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;

[0081] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;

[0082] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 40 μm to obtain amniotic membrane particles.

[0083] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 4% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;

[0084] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;

[0085] Filtering the stirred solution to obtain a filtered solution;

[0086] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.

[0087] S2: dissolving 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0088] 0.2 g of amniotic membrane material, 0.6 g of hydroxyapatite and polyethylene glycol derivative solution were mixed to obtain an osteoinductive filling scaffold material.

[0089] Example 2

[0090] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;

[0091] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;

[0092] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;

[0093] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 1 μm to obtain amniotic membrane particles.

[0094] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 1% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;

[0095] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;

[0096] Filtering the stirred solution to obtain a filtered solution;

[0097] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.

[0098] S2: dissolving 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 3000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0099] 0.05 g of amniotic membrane material, 1.5 g of hydroxyapatite and a polyethylene glycol derivative solution were mixed to obtain an osteoinductive filling scaffold material.

[0100] Example 3

[0101] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;

[0102] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;

[0103] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;

[0104] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 100 μm to obtain amniotic membrane particles.

[0105] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 2% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;

[0106] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;

[0107] Filtering the stirred solution to obtain a filtered solution;

[0108] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.

[0109] S2: dissolving 0.5 g of eight-arm polyethylene glycol succinimidyl succinate with a molecular weight of 10,000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0110] 0.5 g of amniotic membrane material, 2.5 g of hydroxyapatite and a polyethylene glycol derivative solution were mixed to obtain an osteoinductive filling scaffold material.

[0111] Example 4

[0112] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;

[0113] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;

[0114] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;

[0115] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 80 μm to obtain amniotic membrane particles.

[0116] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 6% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;

[0117] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;

[0118] Filtering the stirred solution to obtain a filtered solution;

[0119] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.

[0120] S2: dissolving 0.5 g of eight-arm polyethylene glycol succinimidyl succinate with a molecular weight of 20,000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0121] 0.1 g of amniotic membrane material, 2.0 g of hydroxyapatite and polyethylene glycol derivative solution were mixed and cross-linked to obtain an osteoinductive filling scaffold material.

[0122] Comparative Example 1

[0123] Dissolve 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0124] Dissolve 2% of tri-lysine in a 2.5 ml isotonic phosphate buffer solution at a pH of 7.4 to obtain a tri-lysine buffer solution;

[0125] The polyethylene glycol derivative solution is mixed with tri-lysine buffer to obtain an osteoinductive filling scaffold material.

[0126] Comparative Example 2

[0127] Dissolve 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;

[0128] 0.2 g of amniotic membrane particles with a particle size of 40 μm and not loaded with polyhexamethylene biguanide hydrochloride, 0.6 g of hydroxyapatite and a polyethylene glycol derivative solution were mixed and cross-linked to obtain an osteoinductive filling scaffold material.

[0129] Test Method

[0130] (1) Swelling rate test:

[0131] Weigh 2 g of the bone-inducing filled scaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 and place it in a ground-mouth Erlenmeyer flask, then add a phosphate buffer solution at a temperature of 37° C. and a pH of 7.4 into the ground-mouth Erlenmeyer flask, place the ground-mouth Erlenmeyer flask in an incubator at 37° C., take out the sample every hour, absorb the surface moisture with filter paper, and record the weight again, repeat this process until the weight no longer increases, and calculate the swelling rate.

[0132] The calculation formula is: swelling ratio = (mass of sample after swelling - sampling amount) × 100% / sampling amount, where “ / ” represents “divided by”.

[0133] (2) Tensile strength test:

[0134] The osteoinductive filling scaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 was coated on a polytetrafluoroethylene plate, and then a layer of polytetrafluoroethylene plate was covered on the osteoinductive filling scaffold material to prepare a 2 mm thick film. After solidification, it was cut into strips with a width of 2 cm, and the two ends of the strips were stretched for tensile testing.

[0135] (3) Tensile strength test after one week of in vitro degradation:

[0136] The osteoinductive filling scaffold materials obtained in Examples 1 to 4 or Comparative Examples 1 to 2 were placed in a phosphate buffer isotonic with blood at a temperature of 37° C. and a pH of 7.4 and allowed to stand for one week, and then subjected to the same tensile test as in test method (2).

[0137] (4) Antibacterial test:

[0138] According to the AATCC-100 antibacterial textile evaluation method test method, an antibacterial experiment was conducted. The bone induction filling scaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 was taken as the sample group, and sterile gauze was taken as the blank control group. Staphylococcus aureus bacterial solution was added to the surface of the bone induction filling scaffold material and cultured at 37°C for 24 hours. The number of bacteria when the bacterial solution was added was A, and the number of bacteria remaining after culture was B. The antibacterial performance was judged based on the calculated logarithmic reduction value Y of the number of bacteria.

[0139] Logarithmic reduction of bacterial count Y = lgA – lgB

[0140] (5) Dispersion uniformity test

[0141] The amniotic membrane content ratio in the osteoinductive filling scaffold material of Example 3 is the highest, so the osteoinductive filling scaffold material of Example 3 is selected for dispersion uniformity test.

[0142] Test method: Take the bone induction filling scaffold material and randomly take a volume of 0.5cm 3 The scaffold material was put into 0.5 mol / L sodium hydroxide solution for dissolution. After dissolution, the solution was taken and tested using the protein content test method in Appendix C of "YY / T 0308-2015 Medical Sodium Hyaluronate Gel". The test results are shown in Table 2.

[0143] Experimental results:

[0144] Table 1

[0145]

[0146]

[0147] In the tensile strength test after one week of in vitro degradation, the osteoinductive filling scaffold material of Comparative Example 1 had been mostly degraded and had no tensile strength after one week of in vitro degradation.

[0148] In the antibacterial test, the logarithmic reduction value Y of the bacterial count in the blank control group was -2.3.

[0149] Table 2

[0150]

[0151] The test results showed that the amniotic membrane was evenly distributed in the osteoinductively filled scaffold material.

[0152] in conclusion:

[0153] By comparing the experimental data of Examples 1 to 4 and Comparative Examples 1 to 2, the following conclusions can be obtained:

[0154] (I) The bone-inductive filling scaffold material of the present invention has a lower swelling rate, and the preparation method of the bone-inductive filling scaffold material of the present invention can achieve more uniform dispersion of the amniotic membrane material.

[0155] As can be seen from Table 1, the swelling rates of Examples 1, 3 and 4 are all lower than 7%, and the swelling rate of Example 2 is 10.4%, which is much lower than the swelling rate of 142.2% of Comparative Example 1 and the swelling rate of 53.1% of Comparative Example 2. In the bone-inducing filling scaffold materials of Examples 1 to 4 with low swelling rates, the amniotic membrane material can be evenly dispersed. When the bone-inducing filling scaffold material adheres to the bone defect, the amniotic membrane material contained in its components produces an induction effect, that is, promotes the proliferation and differentiation of recruited cells, and realizes the repair and regeneration of bone defects. The principle of uniform dispersion of the amniotic membrane material is as follows:

[0156] In addition to rich collagen, the amniotic membrane also contains mucopolysaccharides such as sodium hyaluronate and soluble lipid components. The amniotic membrane material containing mucopolysaccharides dissolves and swells when it encounters an aqueous solution, which hinders the infiltration and dispersion of the amniotic membrane material. Therefore, the mucopolysaccharide components in the amniotic membrane are removed by washing. The amniotic membrane material without mucopolysaccharides and soluble lipids contains a large number of hydrophilic groups and can be quickly and evenly dispersed in the solution.

[0157] (II) The bone-inducing filling scaffold material of the present invention has good tensile strength and can maintain a certain tensile strength for a long time.

[0158] As shown in Table 1, first, in the tensile strength test data, the tensile strengths of the osteoinductive filling scaffold materials of Examples 1 to 4 are 2.32MPa, 1.50MPa, 2.97MPa and 2.35MPa, respectively; and the tensile strengths of Comparative Examples 1 and 2 are 0.13MPa and 0.53MPa, respectively. It can be seen that compared with the osteoinductive filling scaffold materials of Comparative Example 1 without amniotic membrane and Comparative Example 2 in which amniotic membrane particles are not loaded with polyhexamethylene biguanide hydrochloride, the osteoinductive filling scaffold materials of Examples 1 to 4 all have good tensile strength.

[0159] Secondly, in the tensile strength test after one week of in vitro degradation, the tensile strength of the osteoinductively filled scaffold materials of Examples 1 to 4 decreased less, and the strength of the osteoinductively filled scaffold materials could still be maintained at more than 80% after one week. In contrast, in Comparative Examples 1 and 2, most of the osteoinductively filled scaffold materials of Comparative Example 1 had been degraded, and the tensile strength of the osteoinductively filled scaffold materials of Comparative Example 2 was reduced by nearly half, from 0.53 MPa to 0.34 MPa.

[0160] It can be seen that the bone-inducing filling scaffold materials of Examples 1 to 4 can maintain a certain strength for a long time. First, the amniotic membrane material therein will not settle over time, but will always remain evenly distributed, ensuring the induction repair effect of the bone defect; second, a three-dimensional scaffold structure is formed, and the amniotic membrane material is evenly distributed in the bone-inducing filling scaffold material. When the bone-inducing filling scaffold material adheres to the bone defect, the three-dimensional scaffold structure gives it good mechanical stability, so no additional fixation is required.

[0161] (III) The bone-inducing filling scaffold material of the present invention has good antibacterial properties.

[0162] As shown in Table 1, compared with the blank control group, in Examples 1 to 4, the logarithmic reduction value Y of the number of bacteria is higher, all around 5, indicating that the bone induction filling scaffold materials of Examples 1 to 4 have good antibacterial properties and the number of bacteria is significantly reduced. On the other hand, in Comparative Examples 1 and 2, the logarithmic reduction value Y of the number of bacteria is lower, all around 0.5, indicating that the bone induction filling scaffold materials of Comparative Examples 1 and 2 have poor antibacterial properties. The specific principle is as follows:

[0163] Polyhexamethylene biguanide hydrochloride has excellent bactericidal properties and excellent biocompatibility. It has strong antibacterial properties and does not affect tissue growth. Polyhexamethylene biguanide hydrochloride strengthens the cross-linking degree of the three-dimensional scaffold while ensuring that the tissue is not infected by bacteria during the repair process. As shown in Table 1, the logarithmic reduction value Y of the biomaterial scaffolds of Examples 1 to 4 for killing bacteria is greater than 4Log.

[0164] The above is only a specific implementation of the embodiment of the present application, but the protection scope of the embodiment of the present application is not limited thereto, and any changes or replacements within the technical scope disclosed in the embodiment of the present application should be included in the protection scope of the embodiment of the present application. Therefore, the protection scope of the embodiment of the present application should be based on the protection scope of the claims.

Claims

1. An osteoinductive filling scaffold material, characterized in that: include: Amniotic membrane material formed by amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride, hydroxyapatite and polyethylene glycol derivative cross-linked with the amniotic membrane material; wherein the mass ratio of the hydroxyapatite, the amniotic membrane material and the polyethylene glycol derivative is 3-30:1:1-10.

2. The osteoinductive filling scaffold material according to claim 1, characterized in that: The polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.

3. The osteoinductive filling scaffold material according to claim 2, characterized in that: The multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.

4. The osteoinductive filling scaffold material according to claim 1, characterized in that: The biological molecular weight of the polyethylene glycol derivative is 3000 to 20000 Daltons.

5. The osteoinductive filling scaffold material according to claim 1, characterized in that: In the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.

6. The osteoinductive filling scaffold material according to claim 1, characterized in that: The mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1 to 10:

1.

7. The osteoinductive filling scaffold material according to claim 6, characterized in that: The polymerization degree of the polyhexamethylene biguanide hydrochloride is 7-17.

8. A method for preparing an osteoinductive filling scaffold material, characterized in that: The following steps are involved: S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material; S2: Mixing the amniotic membrane material, hydroxyapatite and polyethylene glycol derivative solution to obtain the bone-inducing filling scaffold material.

9. The preparation method according to claim 8, characterized in that: The S1 is specifically: Putting the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles into a hydrophilic organic solvent, wherein the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent is 1:10-100, to obtain a mixed solution; Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred mixed solution; Filtering the stirred mixed solution to obtain a filtered mixed solution; The filtered mixed solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.

10. The preparation method according to claim 8, characterized in that: The particle size of the amniotic membrane particles is 1 μm to 100 μm.

11. The preparation method according to claim 8, characterized in that: The mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.

12. The preparation method according to claim 8, characterized in that: The solvent of the polyethylene glycol derivative solution is a buffer solution isotonic with human blood.

13. The preparation method according to claim 9, characterized in that: The hydrophilic organic solvent includes at least one of ethanol, acetone and dimethylformamide.

14. The preparation method according to claim 13, characterized in that: The concentration of the hydrophilic organic solvent is 75 wt % to 95 wt %.

15. The preparation method according to claim 8, characterized in that: Before the S1, the method further includes S0, wherein the S0 includes: The amniotic membrane is sequentially washed, homogenized, freeze-dried and crushed to obtain the amniotic membrane particles, wherein the amniotic membrane is taken from the surface of human placenta or umbilical cord.

16. An application of an osteoinductive filling scaffold material, characterized in that: The osteoinductive filling scaffold material according to any one of claims 1 to 7 is used for preparing a drug for treating bone defects.